Sangamo Therapeutics, Inc. Common Stock, also called Sangamo Therapeutics, is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. Read More It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA. The listed name for SGMO is Sangamo Therapeutics, Inc. Common Stock.